share_log

The Analyst Verdict: Corcept Therapeutics In The Eyes Of 4 Experts

Benzinga ·  May 2 16:01

In the preceding three months, 4 analysts have released ratings for Corcept Therapeutics (NASDAQ:CORT), presenting a wide array of perspectives from bullish to bearish.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings40000
Last 30D20000
1M Ago10000
2M Ago00000
3M Ago10000

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $41.0, along with a high estimate of $44.00 and a low estimate of $38.00. This current average reflects an increase of 6.03% from the previous average price target of $38.67.

price target chart

Diving into Analyst Ratings: An In-Depth Exploration

The standing of Corcept...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment